Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Table 1 Detailed information of potential biomarkers from QDLS compared to QDYD syndrome lung cancer patients

No.	m/z	t_(R)	Identification	Quasi-molecular ion	Formula	VIP	FC	AUC	Trend
1	474.2971	1.6	LPC (O-14:1)	[M + Na]⁺	C₂₂H₄₆NO₆P	1.96	7.44**	0.91	↑
2	518.3212	3.2	LPC (16:0)	[M + Na]⁺	C₂₄H₅₀NO₇P	2.27	0.0029**	1.00	↓
3	564.3279	2.8	LPC (18:2)	[M + HCOO]⁻	C₂₆H₅₀NO₇P	2.02	0.09**	0.91	↓
4	590.3218	2.7	LPC (22:6)	[M + Na]⁺	C₃₀H₅₀NO₇P	1.41	0.56*	0.80	↓
5	454.2926	3.8	LPE (16:0)	[M + H]⁺	C₂₁H₄₄NO₇P	1.55	0.40*	0.88	↓
6	526.2925	2.7	LPE (22:6)	[M + H]⁺	C₂₇H₄₄NO₇P	1.41	0.57*	0.83	↓
7	758.5698	11.2	PC (16:0/18:2)	[M + H]⁺	C₄₂H₈₀NO₈P	1.49	0.52*	0.84	↓
8	792.5924	10.7	PC (P-18:1/20:4)	[M + H]⁺	C₄₆H₈₂NO₇P	1.46	0.58*	0.84	↓
9	766.5394	10.9	PE (16:0/22:5)	[M + H]⁺	C₄₃H₇₆NO₈P	1.45	0.19*	0.83	↓
10	942.7532	17.4	TG (18:2/20:4/20:5)	[M + NH4]⁺	C₆₁H₉₆O₆	1.51	0.10*	0.83	↓

QDLS for whom suffered Qi deficiency of lung-spleen; QDYD for whom suffered Qi deficiency and Yin deficiency; FC fold change, the ion intensity ratio of potential biomarkers from QDLS/QDYD by using the developed UHPLC-Q-TOF/MS method
*p < 0.05 and **p < 0.01, QDLS vs. QDYD group